PC
INDP icon

PA Capital’s Indaptus Therapeutics INDP Stock Holding History

PA Capital’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14
Closed -$225K – 114
2019
Q1 		$225K Buy
+14
New +$245K 0.2% 102

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

PA Capital's INDP Position: Q2 2019 in Review

PA Capital sold out of Indaptus Therapeutics (INDP) in Q2 2019, closing a stake of 14 shares — an estimated $225K sold.

PA Capital first reported a position in INDP in Q1 2019 and held it in 1 quarter. The position peaked at $225K in Q1 2019. 47 funds tracked by Wall St. Rank hold INDP as of Q2 2019.

  • PA Capital reported no remaining Indaptus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • PA Capital sold 14 Indaptus Therapeutics shares in Q2 2019, an estimated $225K.
  • PA Capital first reported a position in Indaptus Therapeutics in Q1 2019 and held it in 1 quarter.
  • PA Capital's Indaptus Therapeutics position peaked at $225K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2019.

Based on PA Capital's 13F filing for Q2 2019, filed 8 Aug 2019.